Physician
Hematology
Dr. Elias J. Jabbour, MD
|
|
Give Review
Dr. Elias J. Jabbour is an expert in the field of Hematology. He went to medical school at St Joseph's University Medical School. Elias J. Jabbour, MD is a published doctor and has 101 publications published. The lastest was: 'Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.' Elias Jabbour is registered with Medicare and accepts Medicare payments.
Publications
- Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
- Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal ...
- Outcomes of patients with myelodysplastic Syndromes who achieve stable disease after treatment with hypomethylating agents.
- Clinical implications of TP53 mutations in myelodysplastic Syndromes treated with hypomethylating agents.
- Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous Leukemia in the era of tyrosine kinase inhibitor ...
- Analysis of 2013 European LeukaemiaNet (ELN) responses in Chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed Acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid Leukemia.
- Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia.
- Role of inotuzumab ozogamicin in the treatment of relapsed/refractory Acute lymphoblastic leukemia.
- Chronic myeloid Leukemia: 2016 update on diagnosis, therapy, and monitoring.
- Interactions and relevance of blast percentage and treatment strategy among younger and older patients with Acute myeloid leukemia (AML) and myelodysplastic syndrome (...
- t(9;22) as secondary alteration in core-binding factor de novo Acute myeloid leukemia.
- Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With...
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive Acute lymphoblastic leukaemia: a single-centre, phase...
- Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
- Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
- Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with Acute lymphoblastic leukaemia.
- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory Acute myeloid leukaemia (VALOR): a randomised, controlled, doubl...
- IDH1 and IDH2 mutations in myelodysplastic Syndromes and role in disease progression.
- Estimated glomerular filtration rate changes in patients with chronic myeloid Leukemia treated with tyrosine kinase inhibitors.
- Inotuzumab ozogamicin in B-cell Acute lymphoblastic leukemias and non-Hodgkin's lymphomas.
- The role of ponatinib in Philadelphia chromosome-positive Acute lymphoblastic leukemia.
- A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes.
- Prognostic factors for outcome in patients with refractory and relapsed Acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
- Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed Acute myeloid leukemia.
- Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed Acute leukemia or high-risk myelodysplastic syndrome.
- Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in Acute myeloid ...
- A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia.
- Deacetylase inhibitors for the treatment of myelodysplastic Syndromes.
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed Acute myeloid leukemia and Acute lymphoblastic leukemia.
- Effectiveness of Homoharringtonine (Omacetaxine Mepesuccinate) for Treatment of Acute Myeloid Leukemia: A Meta-Analysis of Chinese Studies.
- Outcome of patients with low-risk and intermediate-1-risk myelodysplastic Syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research...
- Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in Acute promyelocytic leukaemia.
- Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory Acute lymphocytic leukaemia.
- Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory Acute lymphoblastic leukemia.
- Flow Cytometry Immunophenotypic Findings in Chronic Myelomonocytic Leukemia and Its Utility in Monitoring Treatment Response.
- Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and Acute myelogenous leukemia.
- BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic Leukemia/lymphoma: reduced myelosuppression and GVHD.
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia.
- A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
- Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant Anemia.
- Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with Acute lymphoblastic leukemia (ALL).
- Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acut...
- The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic Syndromes.
- Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation.
- Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid Leukemia.
- Chronic myeloid Leukemia: 2014 update on diagnosis, monitoring, and management.
- A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia.
- Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic Leukemia post clofarabine failure.
- Treating myelodysplastic Syndrome when hypomethylating agents stop working.
- A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
- Clofarabine in the treatment of myelodysplastic Syndromes.
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia.
- Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with Acute myeloid leukemia treated with hypomethylating agents.
- Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with Acute myeloid leukemia.
- Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.
- Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic Syndromes.
- Early response with dasatinib or imatinib in chronic myeloid Leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
- A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
- Allogeneic stem cell transplantation as initial salvage for patients with Acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
- Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid Leukemia.
- Emerging drugs for Acute lymphocytic leukemia.
- Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates.
- Acute Myeloid Leukemia After Myelodysplastic Syndrome and Failure of Therapy With Hypomethylating Agents: An Emerging Entity With a Poor Prognosis.
- Potential mechanisms of disease progression and management of advanced-phase chronic myeloid Leukemia.
- The combination of Hyper-CVAD plus nelarabine as frontline therapy in adult T cell Acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (LL)-MD Anderson c...
- Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic Syndrome is associated with poor prognosis and transformation to acut...
- Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndrom...
- Targeted therapies in hematology and their impact on patient care: chronic and Acute myeloid leukemia.
- HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid Leukemia.
- Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML.
- Expectations of serious adverse events at the end of life of patients with Acute myeloid leukemia who receive salvage therapy.
- Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials.
- Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.
- Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome.
- Significance of deeper molecular responses in patients with chronic myeloid Leukemia in early chronic phase treated with tyrosine kinase inhibitors.
- Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia.
- Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy.
- Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia.
- Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes.
- Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤ 60 years with newly diagnosed Acute myeloid leukemia (AML).
- Modest activity of pomalidomide in patients with myelofibrosis and significant Anemia.
- Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options.
- Management of imatinib-resistant patients with chronic myeloid Leukemia.
- The role of clofarabine in Acute myeloid leukemia.
- Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with Acute...
- Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities.
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed Acute lymphocytic leukemia.
- Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid Leukemia with inadequate response to first-line imatinib.
- Prognostic impact of RAS mutations in patients with myelodysplastic Syndrome.
- The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Mye...
- Prognostic Factors Associated With Disease Progression and Overall Survival in Patients With Myelodysplastic Syndromes Treated With Decitabine.
- Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic Syndrome: A retrospective case-control study.
- Clofarabine Does Not Negatively Impact the Outcomes of Patients With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.
- Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous Leukemia.
- Prognostic significance of 11q23 aberrations in adult Acute myeloid leukemia and the role of allogeneic stem cell transplantation.
- Prediction of outcomes in patients with Ph+ chronic myeloid Leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.
- Rigosertib versus best supportive care for patients with high-risk myelodysplastic Syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled,...
- Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory Myeloid malignancies.
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Education
-
St Joseph's University Medical School
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1215108303 | |
| NPPES Provider LastName | JABBOUR | |
| NPPES Provider FirstName | ELIAS | |
| NPPES Provider ZIPCode | 770304000 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 338.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1215108303 |
| Last Name Of The Provider | JABBOUR |
| First Name Of The Provider | ELIAS |
| View All |
Similar Doctors
|
|
Dr. John M. Carwile, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheeba K. Thomas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chitra Balasundaram, MD |
|
|
Dr. Abhishek V. Marballi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Farhad Ravandi-Kashani, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lixin Zhang, MD |
|
|
Dr. Aditya Shetty, MD |